Novo Nordisk A/S is slashing the cost of Ozempic for cash-paying patients to $499 a month through NovoCare and partnering with GoodRx Holdings Inc. to offer it at the same price at US pharmacies. Bloomberg's Madison Muller reports.

See Full Page